| Title |
Pegylated liposomal doxorubicin for first‐line treatment of epithelial ovarian cancer
|
|---|---|
| Published in |
Cochrane database of systematic reviews, October 2013
|
| DOI | 10.1002/14651858.cd010482.pub2 |
| Pubmed ID | |
| Authors |
Theresa A Lawrie, Roy Rabbie, Clemens Thoma, Jo Morrison |
| Abstract |
Epithelial ovarian cancer (EOC) is often diagnosed at an advanced stage, requiring primary cytoreductive surgery and combination chemotherapy for its first-line management. Currently, the recommended standard first-line chemotherapy is platinum-based, usually consisting of carboplatin and paclitaxel (PAC/carbo). Pegylated liposomal doxorubicin (PLD) is an improved formulation of doxorubicin that is associated with fewer and less severe side effects than are seen with non-modified doxorubicin. In combination with carboplatin, PLD has recently been shown to improve progression-free survival compared with PAC/carbo in women with relapsed, platinum-sensitive EOC. It is therefore important to know whether any survival benefit can be attributed to PLD when it is used in the first-line setting. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 137 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 135 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 20 | 15% |
| Student > Ph. D. Student | 15 | 11% |
| Researcher | 15 | 11% |
| Student > Master | 12 | 9% |
| Other | 11 | 8% |
| Other | 18 | 13% |
| Unknown | 46 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 48 | 35% |
| Nursing and Health Professions | 11 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 5% |
| Biochemistry, Genetics and Molecular Biology | 5 | 4% |
| Psychology | 5 | 4% |
| Other | 10 | 7% |
| Unknown | 51 | 37% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 November 2022.
All research outputs
#7,993,771
of 25,457,858 outputs
Outputs from Cochrane database of systematic reviews
#8,729
of 11,842 outputs
Outputs of similar age
#69,387
of 224,561 outputs
Outputs of similar age from Cochrane database of systematic reviews
#163
of 217 outputs
Altmetric has tracked 25,457,858 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 11,842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 38.9. This one is in the 22nd percentile – i.e., 22% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 224,561 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 217 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.